My world turned upside down when my daughter nearly died from a serious suicide attempt. After several years as her caretaker I began to wonder: What can we do to change the way our mental health services are organized so they won't turn a crisis into a way of life for already distressed and vulnerable people?
The FDA approved the prescribing and sale of a new hi-tech compliance-monitoring “antipsychotic” drug this week. A new chapter in human darkness has descended — one that is applauded by the alliance of control addicts that made it happen.
Schizophrenia has occupied, and continues to occupy, a position of great import in psychiatry, and it is frequently used to assert the supposed biological nature of the field. What evidence is there to suggest that what we call schizophrenia is a disease of the brain? Surprisingly, very little.
Revealing the false information provided about psychiatry should cause any thinking person, patient, thought-leader or politician to wonder: “how many otherwise normal or potentially curable people over the last half century of psych drug propaganda have actually been mis-labeled as mentally ill (and then mis-treated) and sent down the convoluted path of therapeutic misadventures – heading toward oblivion?”
A large study of the population in Taiwan reveals that long-term use of benzodiazepine drugs, commonly prescribed for anxiety, significantly increases the risk for brain, colorectal, and lung cancers. The research, published open-access in the journal Medicine, also identifies the types of benzodiazepines that carry the greatest cancer risk.
Prior use of benzodiazepines, such as Xanax, Librium, or Ativan, may increase the risk of treatment-resistant depression (TRD), according to a new study published in The Journal of Nervous and Mental Disease.
Peer-Support Groups Were Right, Guidelines Were Wrong: Dr. Mark Horowitz on Tapering Off Antidepressants
In an interview with MIA, Dr. Horowitz discusses his recent article on why tapering off antidepressants can take months or even years.
While a great deal of the excitement about advances in psychological treatments comes from the potential for research in neuroscience to unlock the secrets of the brain, many mental health experts would like to temper this enthusiasm. A special issue of the Behavior Therapist released this month calls into question the predominant conception of mental illnesses as brain disorders.
How did I become someone who could barely function? I was a high-performing sales executive ranked in the top 2% of an international business communications company. But now, after using powerful psych meds for depression and anxiety for more than a decade, I couldn’t do basic things like go to the grocery store, plan a meal, make dinner, or get together with friends.
A new study, published this month in the Journal of Affective Disorders, investigated the effectiveness of weekly intravenous ketamine injections as a treatment for...
Study finds that reduced cortical thickness and brain surface area associated with 'schizophrenia' may result from antipsychotic drug use.
Recently, I have been the target of much wooing by my local Sunovion rep. I think he leaves messages for me almost weekly and he sends me missives - glossy brochures and reprints from major psychiatric journal. What is the subject of this attention? The drug - lurasidone (Latuda).
Antidepressants may be effective over the short term, but research is showing that treatment resistant depression has risen dramatically in the past 30 years; evidence that the drugs may be inducing chronic depression.
Bipolar drug therapy is a balancing act of benefits vs. harms. Odds of attributable benefit cluster in a 15-25% band, so 75%-85% don’t see substantial benefit. Stated differently, if five people take a bipolar drug, only one is likely to see substantial improvement due to it, but all five will have side effects.
In-depth interviews find that those who screened positive for depression did not explain their experience in terms of diagnostic symptoms.
A new study finds poorer depression and anxiety outcomes in psychotherapy for people in economically deprived neighborhoods and those on antidepressants.
Findings suggest that treatment not only fails to reduce the severity of “ADHD” symptoms in adulthood but is associated with decreased height.
Allen Frances has claimed that "It's a great mistake to confuse bad behavior with mental illness." Yet two of the so-called mental illnesses (conduct disorder and antisocial personality disorder) consist essentially of "bad" behavior, while in at least six others, "bad" behavior is an integral part of the problem.
With increasing evidence that psychiatric drugs do more harm than good over the long term, the field of psychiatry often seems focused on sifting through the mounds of research data it has collected, eager to at last sit up and cry, here’s a shiny speck of gold! Our drugs do work! One recently published study on withdrawal of antipsychotics tells of long-term benefits. A second tells of long-term harm. Which one is convincing?
Effects of discontinuing SSRIs and SNRIs reported on an online forum indicate significant and long-lasting withdrawal symptoms.
As a psychiatric survivor who has personally experienced severe psychosis, my criticisms focus on the relative lack of attention to what psychiatric drugs actually are, and on the uncertain, contested nature of the supposed target of these drugs: “schizophrenia.” I will elaborate on each of these points with references, as well as highlighting alternative approaches to helping psychotic people.
A new review, published in BMJ Evidence-Based Medicine, concludes that antidepressants should not be used as the risks outweigh evidence for benefits.
The published report of the Broaden Trial of Deep Brain Stimulation for Depression whitewashed the results: although the efficacy results were negative, the investigators concluded that the therapy still showed "promise", and adverse events suffered by the patients were downplayed or attributed to the disease, and not the treatment. An in-depth investigation of how the trial results were spun, and interviews with patients that tell of harm done.
It makes sense to be cautious about any kind of exploratory practice that might send someone who has been "psychotic" into another period of being lost and confused. But we should also beware the risk of trying to be too stable and "normal" after psychosis — the risk of avoiding the transformative work that might need to happen for that person.
Why, despite the fact that the vast majority of people diagnosed with a mental illness have suffered from some form of childhood trauma, is it still so difficult to talk about? Why, despite the enormous amount of research about the impact of trauma on the brain and subsequent effect on behaviour, does there seem to be such an extraordinary refusal for the implication of this research to change attitudes towards those who are mentally ill? Why, when our program and others like it have shown people can heal from the effects of trauma, are so many people left with the self-blame and the feeling they will never get better that my colleague writes about below?